| Name | Title | Contact Details |
|---|
LE JACQ is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hilton East Assisted Living is a 205 bed community nestled in the peaceful village of Hilton , NY. Our staff has a track record of quality care that spans over 30 years. We have been providing impeccable care since 1974. We provide more care hours per
Myelin Health is a network of companies linked by their experience and capabilities in the healthcare space. For payer and provider organizations, we create connections that make the most powerful messages mean even more. Myelin Health operates a strong and collaborative system of communication experts with capabilities in creative digital and traditional solutions, strategy and branding concepts, integrated marketing and advertising content, research, data and analytics, mobile engagement, design and more.
SEIU-UHW is Working for a Healthy California Service Employees International Union-United Healthcare Workers West (SEIU-UHW) is a California union made up of 150,000 healthcare workers who work in hospitals, nursing homes, and in the community as home care providers. Our members are frontline caregivers, including respiratory care practitioners, dietary, environmental services and nursing staff who keep Californians healthy. We live and work throughout California: from the Bay Area to Sacramento and Los Angeles to the Central Valley. Our union of healthcare workers is driven to improve the healthcare system. Our mission is to provide quality care for all patients, expand access to excellent, affordable healthcare for all Californians and improve living standards for all workers.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.